UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 5.

Rauch, P J; Ellegast, J M; Widmer, C C; Fritsch, K; Goede, J S; Valk, P J; Löwenberg, B; Takizawa, H; Manz, M G (2016). MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia. Blood, 128(18):2253-2257.

Versluis, J; In't Hout, F E; Devillier, R; van Putten, W L; Manz, M G; Vekemans, M C; Legdeur, M C; Passweg, J R; Maertens, J; Kuball, J; Biemond, B J; Valk, P J; van der Reijden, B A; Meloni, G; Schouten, H C; Vellenga, E; Pabst, T; Willemze, R; Löwenberg, B; Ossenkoppele, G; Baron, F; Huls, G; Cornelissen, J J (2016). Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia, 31(1):26-33.

Cornelissen, J J; Versluis, J; Passweg, J R; van Putten, W L; Manz, M G; Maertens, J; Beverloo, H B; Valk, P J; van Marwijk, Kooy M; Wijermans, P W; Schaafsma, M R; Biemond, B J; Vekemans, M C; Breems, D A; Verdonck, L F; Fey, M F; Jongen-Lavrencic, M; Janssen, J J; Huls, G; Kuball, J; Pabst, T; Graux, C; Schouten, H C; Gratwohl, A; Vellenga, E; Ossenkoppele, G; Löwenberg, B (2015). Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia, 29(5):1041-1050.

Terwijn, M; van Putten, W L; Kelder, A; van der Velden, V H; Brooimans, R A; Pabst, T; Maertens, J; Boeckx, N; de Greef, G E; Valk, P J; Preijers, F W; Huijgens, P C; Dräger, A M; Schanz, U; Jongen-Lavrecic, M; Biemond, B J; Passweg, J R; van Gelder, M; Wijermans, P; Graux, C; Bargetzi, M; Legdeur, M C; Kuball, J; de Weerdt, O; Chalandon, Y; Hess, U; Verdonck, L F; Gratama, J W; Oussoren, Y J; Scholten, W J; Slomp, J; Snel, A N; Vekemans, M C; Löwenberg, B; Ossenkoppele, G J; Schuurhuis, G J (2013). High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON/SAKK AML 42A Study. Journal of Clinical Oncology, 31(31):3889-3897.

Lugthart, S; Gröschel, S; Beverloo, H B; Kayser, S; Valk, P J; van Zelderen-Bhola, S L; Ossenkoppele, G J; Vellenga, E; van den Berg-de Ruiter, E; Schanz, U; Verhoef, G; Vandenberghe, P; Ferrant, A; Köhne, C H; Pfreundschuh, M; Horst, H A; Schlegelberger, H; Jotterand, M; Krauter, J; Pabst, T; Theobald, M; Schlenk, R F; Delwel, R; Döhner, K; Löwenberg, B; Döhner, H (2010). Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. Journal of Clinical Oncology, 28(24):3890-3899.

This list was generated on Mon Jul 24 02:55:05 2017 CEST.